Menu Search
Equities

Bioasis Technologies Inc

107:DEU

Bioasis Technologies Inc

Actions
  • Price (EUR)0.008
  • Today's Change0.00 / 0.00%
  • Shares traded180.00k
  • 1 Year change-38.46%
  • Beta--
Data delayed at least 15 minutes, as of Mar 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

  • Revenue in CAD (TTM)269.38k
  • Net income in CAD-2.88m
  • Incorporated2006
  • Employees--
  • Location
    Bioasis Technologies Inc22420 Dewdney Trunk Road, Suite 300BURNABY V2X 3J5CanadaCAN
  • Phone+1 (604) 295-7014
  • Fax+1 (604) 278-8785
  • Websitehttps://www.bioasis.us/contact/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.